In 2020, Genomeditech established the professional cell line sub-brand DDXCELL, providing services and related products such as reporter gene testing, virus packaging, engineered cell line construction, gene editing, and drug screening evaluation to empower drug development processes.
Understanding the molecular functional mechanisms and in vitro activity validation of antibody drugs is a necessary prerequisite for CMC development in the early stages of antibody drug discovery. Engineered cell lines for validation connect drug discovery with preclinical development, serving as a critical step in early drug screening. The application range, validation data, and stability of cell lines directly impact the progress of drug screening.
Genomeditech's self-developed cell line products can meet the application evaluation of small molecules, monoclonal antibodies, bispecific antibodies, etc., in early screening, binding, in vitro biological activity, and animal immunology.
